秋水仙碱早期给药对60岁以上COVID-19肺炎高危患者有效性的研究方案
COLCHICOVID研究是一项由研究者发起的随机、多中心、对照、开放标签、平行分组(2:1)III期临床试验,旨在评估早期使用秋水仙碱能否减少60岁以上伴有高危合并症的COVID-19患者发生严重肺部并发症。该研究在初级卫生保健中心开展,采用务实设计,以贴合常规临床实践。
要点
- 研究针对60岁以上、有高危合并症的COVID-19患者,在初级保健中心早期给予秋水仙碱。
- 主要目的是评估秋水仙碱减少严重肺部并发症的效果,设计为随机对照开放标签III期试验。
- 秋水仙碱具有抗炎、抗纤维化、可能抑制病毒复制及抑制凝血激活等药理特性。
核心结论
- 早期使用秋水仙碱可能降低脆弱患者COVID-19的死亡率和严重肺部并发症,但尚需试验验证。
研究设计与样本
- COLCHICOVID研究为随机、多中心、对照、开放标签、平行分组(2:1比例)、III期临床试验。
- 研究对象为60岁以上伴有高危合并症的COVID-19患者,在初级卫生保健中心开展。
- 试验注册号NCT04416334,注册日期2020年6月4日,方案版本v3.0(2020年9月22日)。
临床怎么用
- 若证实有效,早期秋水仙碱可缓解卫生系统压力并避免疫情波浪中医疗崩溃。
- 秋水仙碱为已知药物,在初级保健环境中使用简单且成本低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no strong evidence that any drug is beneficial either for the treatment of SARS-CoV-2 disease or for post-exposure prophylaxis. Therefore, clinical research is crucial to generate results and evaluate strategies against COVID-19. Primary care (PC) centers, the first level of care in the health system, are in a favorable position to carry out clinical trials (CD), as they work with a large volume of patients with varied profiles (from acute to chronic pathologies). During the COVID-19 pandemic, the need for hospital admission and mortality is higher in people > 60 years. Therefore, this is a target population to try to reduce the serious complications and lethality of COVID pneumonia and to avoid overloading the hospital system. Given the pharmacological properties of colchicine (anti-inflammatory and anti-fibrotic, possible inhibition of viral replication, and inhibitory effect on coagulation activation), early treatment with colchicine may reduce the rate of death and serious pulmonary complications from COVID-19 in vulnerable patients. METHODS: The COLCHICOVID study is a randomized, multicenter, controlled, open-label parallel group (2:1 ratio), phase III clinical trial to investigate the efficacy of early administration of colchicine in reducing the development of severe pulmonary complications associated with COVID-19 infection in patients over 60 years of age with at-risk comorbidities. DISCUSSION: This is a pragmatic clinical trial, adapted to usual clinical practice. The demonstration that early administration of colchicine has clinical effectiveness in reducing the complications of SARS-CoV-2 infection in a population highly susceptible may mitigate the health crisis and prevent the collapse of the health system in the successive waves of the coronavirus pandemic. In addition, colchicine is a well-known medicine, simple to use in the primary care setting and with a low cost for the health system. TRIAL REGISTRATION: ClinicalTrials.gov NCT04416334 . Registered on 4 June 2020. Protocol version: v 3.0, dated 22 September 2020.
引用
- Estebanez EB, Alconero LL, Fernández BJ, et al. The effectiveness of early colchicine administration in patients over 60 years old with high risk of developing severe pulmonary complications associated with coronavirus pneumonia SARS-CoV-2 (COVID-19): study protocol for an investigator-driven randomized controlled clinical trial in primary health care-COLCHICOVID study. Trials. 2021. PMID: 34488841. doi:10.1186/s13063-021-05544-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。